Refine Technology, LLC (Refine), the developer and worldwide supplier to the biotech industry of the ATF™ System, a best-in-class cell retention device, and Gallus BioPharmaceuticals, LLC (Gallus), the industry leading contract bulk biopharmaceuticals manufacturer, today announced a collaboration to optimize continuous cell culture processes.
In a paper published by Cell Host and Microbe on Feb. 13, a research team led by Blossom Damania, PhD, of the Department of Microbiology and Immunology and member of the UNC Lineberger Comprehensive Cancer Center, found that suppressing the TLK enzyme causes the activation of the lytic cycle of both EBV and KSHV. During this active phase, these viruses begin to spread and replicate, and become vulnerable to anti-viral treatments.
Improving manufacturing process efficiencies is a continuous endeavor in the life sciences industry. In today’s fiercely competitive markets, it has become necessary to regularly evaluate cost position to increase profitability and customer satisfaction. By Christine Banaszek, Charles Ross & Son Company
The ÄKTA™ pcc 75 chromatography system can be used for purification of target proteins in continuous downstream processes using periodic counter-current chromatography (PCC). PCC enables greater utilization of the chromatography medium (resin) capacity, allowing sample loading to much higher levels compared with what is possible in traditional batch chromatography.
Bulk transportation of temperature sensitive pharmaceuticals and biologics has become a common practice due to complex global supply chains. By Iftekhar Ahmed, Ben VanderPlas, and Stu Krupnick
Biosimilars are considered to be one of the fastest growing sectors of the pharmaceutical industry.
L-Methionine sulfoximine (MSX) inhibits the activity of glutamine synthetase (GS), an enzyme essential for the production of glutamine. MSX can be used as a media supplement to aid selection and amplification processes in recombinant mammalian cell lines that use GS as a selective marker.
The aim with this white paper is to discuss the advantages of using Capto Core 700 in virus purification compared to size exclusion chromatography (SEC), a technique commonly used in several vaccine processes.
This white paper from BIO-G looks at how to create flexible, agile manufacturing facilities to respond to the current glut of biomanufacturing capacity and industry consolidation. Future proofing these facilities for higher titers and multiple product lines is also explored.
America's biopharmaceutical companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).
Research peptides are used around the world for a number of reason but most notably to test the effects of growth hormone related hormones and growth hormone related peptides and their effects.
Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today provided an overview on the early breast cancer competitive status of the lead cancer immunotherapy product, AE37, under development at its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com).
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed a non-exclusive license agreement with Amgen Inc. for access to DSM's proprietary XD® high cell density process patents.
BioInvent International AB recently announced that Svein Mathisen has resigned from his positions as chief executive officer of the Company and as member of the Board of Directors.
Glen Allen, VA /PRNewswire/ - Star Scientific, Inc. (NASDAQ: STSI) announced today the preliminary results of the Company's ASAP (Anatabloc Supplementation Autoimmune Prevention) Human Thyroid Study that analyzes the impact of anatabine dietary supplementation on thyroid health.
Gradalis, Inc. today announced that is has closed a $24 million Series B round of financing. Gradalis will use the funding to advance its autologous vaccine platform, FANG™, through late-stage clinical trials and expand manufacturing capabilities to accommodate commercial launch of FANG.
ArmaGen Technologies, Inc., a leader in the delivery of biotherapeutics targeting the central nervous system (CNS), today announced James Callaway , Ph.D. as Chief Executive Office and member of the Board of Directors.